| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T260 |
0-136 |
Sentence |
denotes |
Treating neurological symptoms can be challenging as drugs that suppress the immune system may be contraindicated for COVID-19 patients. |
| T261 |
137-224 |
Sentence |
denotes |
There is evidence that the use of corticosteroids may prolong viral shedding [119,120]. |
| T262 |
225-547 |
Sentence |
denotes |
Symptoms for neurological problems may be addressed, with first-line strategies such as controlling body temperature, offering anticonvulsants, and treating hypoxia.21 Second-line treatments for neuroinflammation involve IV immunoglobulin or plasma exchange, but IV immunoglobulin may increase the risk of thromboembolism. |
| T263 |
548-652 |
Sentence |
denotes |
Furthermore, there is emerging concern of the possibility of microthrombosis in COVID-19 patients [121]. |
| T264 |
653-819 |
Sentence |
denotes |
Third-line strategies for neuroinflammation in COVID patients may carry higher risks, and include such pharmacological agents as cyclophosphamide and rituximab [121]. |
